Drusen evolution affects photoreceptor IS/OS junction integrity

Article

The photoreceptor inner segment/outer segment (IS/OS) junction integrity can be affected by drusen evolution.

The photoreceptor inner segment/outer segment (IS/OS) junction integrity can be affected by drusen evolution, according to a study in Retina.

Dr Kathrin Hartmann et al., Department of Ophthalmology, University of California, California, USA, performed drusen volume raster scans through 2624 drusen in 14 eyes with clinically dry age-related macular degeneration (AMD).

All eyes were longitudinally followed up between 23 and 28 months without intervention and a total of 416 of the drusen scanned were analysed for the study.

Of the drusen studied, 20% regressed spontaneously, 51% demonstrated no change in size and 29% progressed. The mean drusen size was 63.7 ± 25.7 μm. The cross-sectional analysis of drusen morphology revealed a link between drusen size and disrupted IS/OS junction/photoreceptor integrity. The IS/OS junction integrity was intact in the drusen that regressed over time.

Drusen evolution can cause structural disruption of the IS/OS junction and after drusen regression the IS/OS junction can either restore drusen regression or artifactitiously compress it.

The abstract for this study can be found here here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.